AKT1 and osteosarcoma: Huang et al.found that luteolin can target multiple targets of osteosarcoma through network pharmacology analysis, especially key genes in the PI3K-AKT signaling pathway, such as AKT1, IL6, JUN, STAT3, TNF, and VEGFA.